An Open-Label, Multi-Drug, Multi-Centre, Phase II Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

Summary

This is a Phase II, open-label, multi-drug, multi-centre study designed to assess the efficacy, safety, tolerability, pharmacokinetics, and immunogenicity of novel combination therapies in participants with locally advanced unresectable or metastatic gastric or GEJ adenocarcinoma.

Description

Eligibility

Age range

18+ years

Sex

All

Healthy volunteers

No

Interventions

• Drug
  Rilvegostomig

  an anti PD-1 and anti-TIGIT bispecific antibody; IV infusion

• Drug
  Volrustomig

  an anti PD-1 and anti CTLA-4 bispecific antibody; IV infusion

• Drug
  FOLFOX

  5-fluorouracil oxaliplatin, leucovorin (levoleucovorin when locally preferred and available)

• Drug
  XELOX

  capecitabine and oxaliplatin

• Drug
  AZD0901

  an anti Claudin18.2 ADC; IV infusion

• Drug
  5-Fluorouracil

  5-FU, IV infusion

• Drug
  Capecitabine

  Oral take

Locations (44)